Automate Your Wheel Strategy on MRK
With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRK
- Rev/Share 25.7146
- Book/Share 20.7566
- PB 4.8703
- Debt/Equity 0.798
- CurrentRatio 1.6612
- ROIC 0.2431
- MktCap 254059866560.0
- FreeCF/Share 5.2238
- PFCF 19.4697
- PE 13.2669
- Debt/Assets 0.372
- DivYield 0.0324
- ROE 0.3895
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | MRK | BMO Capital Markets | Market Perform | Outperform | -- | $130 | Dec. 18, 2025 |
| Upgrade | MRK | Wells Fargo | Equal Weight | Overweight | -- | $125 | Nov. 24, 2025 |
| Initiation | MRK | Scotiabank | -- | Sector Outperform | -- | $105 | Nov. 13, 2025 |
| Resumed | MRK | Citigroup | -- | Neutral | -- | $95 | Oct. 13, 2025 |
| Downgrade | MRK | Berenberg | Buy | Hold | -- | $90 | Sept. 17, 2025 |
| Downgrade | MRK | Citigroup | Buy | Neutral | -- | $84 | May 14, 2025 |
| Initiation | MRK | Cantor Fitzgerald | -- | Neutral | -- | $85 | April 22, 2025 |
| Downgrade | MRK | Deutsche Bank | Buy | Hold | $128 | $105 | Feb. 18, 2025 |
| Downgrade | MRK | TD Cowen | Buy | Hold | $121 | $100 | Feb. 10, 2025 |
| Downgrade | MRK | Truist | Buy | Hold | -- | $110 | Jan. 8, 2025 |
News
Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
Read More
Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans
Published: December 19, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Reaches Agreement With U.S. Government to Expand Access to Medicines and Lower Costs for Americans.
Read More
Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out
Published: December 19, 2025 by: Benzinga
Sentiment: Negative
Merck & Co. Inc. (NYSE: MRK) will not exercise its option for Evaxion A/S (NASDAQ: EVAX) Gonorrhea vaccine candidate EVX-B2.
Read More
Can Merck Successfully Steer Through the Upcoming Headwinds?
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
MRK faces looming Keytruda LOE, falling Gardasil sales and pricing pressure, but new products, pipeline and planned cost savings aim to offset the headwinds.
Read More
Here's Why Merck (MRK) is a Strong Growth Stock
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Trump to announce new drug-pricing deals later today
Published: December 19, 2025 by: Market Watch
Sentiment: Positive
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Read More
Eli Lilly or Merck: Where Should Investors Put Their Money?
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.
Read More
MRK Gets Positive CHMP Opinion for Expanded Use of Winrevair in PAH
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck secures a positive CHMP opinion to expand Winrevair's PAH use, potentially broadening treatment to adult patients across WHO FC II-IV.
Read More
Can MRK's New Drugs & Pipeline Help Navigate the Looming Keytruda LOE?
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.
Read More
Dividend Stocks for 2026: Where to Invest as the Market Cools
Published: December 10, 2025 by: MarketBeat
Sentiment: Positive
As we enter the final stretch of 2025, it's clear that this has been a strong year for equities. However, with valuations across the tech sector stretched and talk of an AI-fueled bubble growing louder, many investors are beginning to look for more stable, income-generating opportunities.
Read More
MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy?
Published: December 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
Merck holds bullish momentum as pipeline advances and major deals offset vaccine weakness and Keytruda risks.
Read More
FDA approves Merck drug for decimated U.S. cattle herds to stop screwworm
Published: December 09, 2025 by: CNBC
Sentiment: Positive
The U.S. Food and Drug Administration granted conditional approval for a Merck Animal Health pour-on treatment for the prevention and treatment of New World Screwworm, with farmers able to receive doses by December 20. U.S. cattle herds are at historic lows, pressuring beef prices, with the parasite from Mexico among multiple reasons for the decline in ranchers' livestock.
Read More
Watch 5 Bigwigs in December After Double-Digit Returns Past Month
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Five market giants, CVNA, WMT, AMAT, FCX and MRK, delivered double-digit returns last month with more room to run in December.
Read More
Can Merck's New Products Aid Growth as Keytruda LOE Test Looms?
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Positive
MRK banks on Capvaxive, Winrevair and other new launches to counter Keytruda's looming 2028 LOE and record long-term growth.
Read More
FDA Conditionally Approves Merck Animal Health's EXZOLT™ CATTLE-CA1 for the Prevention and Treatment of New World Screwworm (Cochliomyia hominivorax) Larvae (myiasis)
Published: December 04, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the U.S. Food and Drug Administration (FDA) has granted a conditional approval for EXZOLT™ CATTLE-CA1 (fluralaner topical solution). This innovative product is in the newest class of parasiticides known as isoxazolines. The pour-on solution is effective for the prevention and treatment of infest.
Read More
Why Merck (MRK) is a Top Growth Stock for the Long-Term
Published: December 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Top 10 High-Yield Dividend Stocks For December 2025
Published: December 01, 2025 by: Seeking Alpha
Sentiment: Positive
The November 2025 high-yield dividend watchlist delivered a 2.94% gain in last month, outperforming SPY and closely trailing VYM. This watchlist blends quality and value to identify high-yield stocks with attractive valuations, aiming for a 12% long-term CAGR and strong starting yields. Top 10 picks for December include Accenture, EOG Resources, Nike, Paychex, ADP, Penske Automotive, Comcast, Essential Utilities, and Brown Forman.
Read More
Here's Why Merck (MRK) is a Strong Momentum Stock
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Merck: Excellence Across The Board
Published: November 28, 2025 by: Seeking Alpha
Sentiment: Positive
Merck (MRK) demonstrates excellence across the board through its resilient revenue mix, expanding profitability, and stellar capital allocation. MRK's innovation, highlighted by Keytruda's dominance and diversified revenue streams, supports strong profitability and mitigates concentration risk. MRK's proven investment track record and consistent dividend growth further reinforce its appeal as a long-term investment opportunity.
Read More
AstraZeneca or Merck: Which Oncology Giant Has the Edge?
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
AZN and MRK boast major oncology strengths and expanding pipelines amid shifting market dynamics in this pharma matchup.
Read More
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Will Soft Gardasil Demand Continue to Dampen Merck's Top Line?
Published: November 26, 2025 by: Zacks Investment Research
Sentiment: Negative
MRK faces steep Gardasil declines as China and Japan demand soften, putting pressure on its vaccine portfolio.
Read More
FDA Approves MRK's Keytruda & Keytruda SC Combo in Bladder Cancer
Published: November 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck gains FDA nod for Keytruda and Keytruda Qlex with Padcev in MIBC, marking the first PD-1 inhibitor plus ADC regimens for this patient group.
Read More
Pharma Stock Pops on Wells Fargo Upgrade
Published: November 24, 2025 by: Schaeffers Research
Sentiment: Positive
Pharmaceutical stock Merck & Co (NYSE:MRK) is up 4% at $101.64 at last glance, after an upgrade from Wells Fargo to "overweight" from "equal weight," with a price-target hike to $125 from $90.
Read More
Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference 2025 Transcript
Published: November 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Merck & Co., Inc. ( MRK ) Jefferies London Healthcare Conference 2025 November 20, 2025 9:30 AM EST Company Participants Peter Dannenbaum - Vice President of Investor Relations Chirfi Guindo - Senior VP & Chief Marketing Officer of Human Health Marjorie C. Green - Senior VP & Head of Late-Stage Oncology - Global Clinical Development Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Last day.
Read More
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
Published: November 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
Read More
Here's Why Merck (MRK) is a Strong Value Stock
Published: November 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment
Published: November 19, 2025 by: Benzinga
Sentiment: Positive
Merck & Co. Inc. (NYSE: MRK) on Wednesday shared topline results from the Phase 3 trial of an investigational, once-daily, oral, two-drug, single-tablet regimen of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection who had not previously received antiretroviral treatment (treatment-naïve).
Read More
Merck Stock Rise as New PAH Drug Winrevair Meets Goal in Another Study
Published: November 19, 2025 by: Zacks Investment Research
Sentiment: Positive
MRK's Winrevair hits its phase II goal in patients with CpcPH tied to HFpEF, setting up phase III plans and a potential path to broader use. Stock up.
Read More
Merck's Winrevair Success Extends Beyond Pulmonary Hypertension, Showing Promise In Complex Heart Condition
Published: November 18, 2025 by: Benzinga
Sentiment: Positive
Merck & Co. Inc. (NYSE: MRK) on Tuesday released topline results from the Phase 2 CADENCE study of Winrevair (sotatercept-csrk) in adults for combined post- and precapillary pulmonary hypertension (CpcPH) due to heart failure with preserved ejection fraction (HFpEF).
Read More
About Merck & Co., Inc. (MRK)
- IPO Date 1978-01-13
- Website https://www.merck.com
- Industry Drug Manufacturers - General
- CEO Robert Davis
- Employees 73000